Futu Information report dated June 29, this Wednesday $MICROPORT NEURO (02172.HK)$Announced that the offering will take place from June 29 to July 8. The company plans to issue 13.7 million shares, including 1.37 million shares for public offering and 12.33 million shares for international offering. The issue price is HKD 24.64 per share, with a minimum lot size of 1,000 shares, and it is expected to be listed on July 15.
The company is a Chinese firm in the neuro-interventional medical device industry, committed to providing innovative solutions to doctors and patients. Since the approval of its first product in 2004, as of the latest practicable date, the company has accumulated a portfolio of 30 products, including ten treatment products and three access products approved and commercialized in China, along with 17 candidate products under development.
The company has a comprehensive portfolio of approved therapeutic products covering three major areas of cerebrovascular diseases: hemorrhagic stroke, cerebral arteriosclerosis stenosis, and acute ischemic stroke. According to Frost & Sullivan, in terms of revenue in 2020, the company is the only Chinese company among the top five players in China's neuro-interventional medical device market, holding approximately 4% market share.
According to Frost & Sullivan, regarding hemorrhagic stroke, which represents the largest segment in terms of product sales in China’s neuro-interventional medical device industry, the company has commercialized products in key therapeutic categories, including embolic coils, flow-diverting stents, and covered stents. In addition to approvals in China...